PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment
1. BMRN's Palynziq shows favorable Phase 3 results in adolescents with PKU. 2. 45% of Palynziq patients achieved significant reduction in phenylalanine levels. 3. Competition from PTC's Sephience poses risks to Palynziq's market uptake. 4. Analysts expect modest revenue growth from the adolescent indication. 5. BMRN's Voxzogo faces headwinds from upcoming regulatory decisions.